The motivations, barriers, and sociodemographic characteristics of healthy Chinese volunteers in phase I research

被引:4
|
作者
Wang, Zejuan [1 ]
Chen, Gang [1 ]
Liu, Xiaona [1 ]
Liu, Chen [2 ]
Song, Qingkun [3 ]
Wang, Jin [1 ]
机构
[1] Aerosp Ctr Hosp, Dept Clin Pharmacol, 15 Yuquan Rd, Beijing 100049, Peoples R China
[2] Capital Med Univ, Beijing Shijitan Hosp, Phase Clin Trial Ctr 1, 10 Tieyi Rd, Beijing 100038, Peoples R China
[3] Capital Med Univ, Beijing Shijitan Hosp, Dept Sci & Technol, 10 Tieyi Rd, Beijing 100038, Peoples R China
关键词
Healthy volunteers; Recruitment; Participation; Motivations; Barriers; Willingness; CLINICAL-RESEARCH; PARTICIPATE; WILLINGNESS; ATTITUDES; DECISION; MOTIVES; PAYMENT; TRIALS; RISKS;
D O I
10.1007/s00228-020-03040-6
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose To describe the motivations, barriers, and sociodemographic characteristics of healthy Chinese volunteers in phase I research and to demonstrate the factors influencing their willingness to participate in subsequent trials. Methods Healthy subjects who participated in seven phase I trials at two centres were invited to participate in the cross-sectional survey at discharge by anonymously and voluntarily completing the self-administered questionnaire. Results From 442 subjects asked to complete the questionnaire, a response rate of 94.8% (419) was obtained, and 72.8% of the respondents had participated in a mean of 2.0 +/- 1.3 previous studies. Over 90% of the subjects indicated that the main motivations to participate trials were to help more people, to contribute to scientific research, and to obtain money. The top 5 barriers were time inconvenience, advertisement sources, potential risks associated with the drug, privacy, and the route of drug administration. Nearly half (49.6%) of the subjects were willing to participate in the next trial. The factors impacting the willingness of the subjects to participate in subsequent trials were gender, screening frequency, enrolment frequency, level of understanding of the research, two motivating factors (to make money and receive a free check-up), and ten barriers (e.g. risk, distance, living conditions, and trust). Conclusions The majority of healthy Chinese subjects were young, were less well educated, had low income levels, and had poor medical insurance coverage. Given the multiple sources of motivation and complex barriers to trial participation, investigators and recruitment staff should consider ethics aspects to guarantee volunteer safety and well-being.
引用
收藏
页码:557 / 568
页数:12
相关论文
共 50 条
  • [21] Phase I Clinical Study of Edaravone in Healthy Chinese Volunteers Safety and Pharmacokinetics of Single or Multiple Intravenous Infusions
    Li, Hao
    Xu, Kun
    Wang, Yongqing
    Zhang, Hongwen
    Li, Tianping
    Meng, Ling
    Gong, Xiaojian
    Zhang, Haibo
    Ou, Ning
    Ruan, Jinman
    DRUGS IN R&D, 2012, 12 (02) : 65 - 70
  • [22] Phase i clinical study of edaravone in healthy Chinese volunteers: Safety and pharmacokinetics of single or multiple intravenous infusions
    Li H.
    Xu K.
    Wang Y.
    Zhang H.
    Li T.
    Meng L.
    Gong X.
    Zhang H.
    Ou N.
    Ruan J.
    Drugs in R&D, 2012, 12 (2) : 65 - 70
  • [23] Patients’ motivations and interest in research: Characteristics of volunteers for patient-led projects on PatientsLikeMe
    Bradley M.
    Braverman J.
    Harrington M.
    Wicks P.
    Research Involvement and Engagement, 2 (1)
  • [24] Phase I safety and pharmacokinetic study of magnesium isoglycyrrhizinate after single and multiple intravenous doses in Chinese healthy volunteers
    Sun, Li
    Shen, Jinfang
    Pang, Xiaoyun
    Lu, Lungen
    Mao, Yimin
    Zeng, Minde
    JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 47 (06): : 767 - 773
  • [25] The Lipid-lowering Effects of R-bambuterol in Healthy Chinese Volunteers: A Randomized Phase I Clinical Study
    Ye, Yanrui
    Xu, Hang
    Quan, Lei
    Zhu, Long
    Zeng, Jing
    Zhou, Ting
    Zou, ChengJuan
    Cheng, Qing
    Bu, Shujie
    Tan, Wen
    EBIOMEDICINE, 2015, 2 (04): : 356 - 364
  • [26] Healthy Volunteers' Perceptions of the Benefits of Their Participation in Phase I Clinical Trials
    Fisher, Jill A.
    McManus, Lisa
    Wood, Megan M.
    Cottingham, Marci D.
    Kalbaugh, Julianne M.
    Monahan, Torin
    Walker, Rebecca L.
    JOURNAL OF EMPIRICAL RESEARCH ON HUMAN RESEARCH ETHICS, 2018, 13 (05) : 494 - 510
  • [27] Carnosine increases cardiac output in a phase I trial in healthy volunteers
    Shah, AJ
    Groban, L
    Dolinski, SY
    Wall, MH
    Shouse, MN
    Prielipp, RC
    Roberts, PR
    CRITICAL CARE MEDICINE, 2000, 28 (12) : A45 - A45
  • [28] A phase I study of AIT-082 in healthy elderly volunteers
    Michael Grundman
    Martin Farlow
    Guerry Peavy
    Hyun T. Kim
    Edmund Capparelli
    Arlan N. Schultz
    David P. Salmon
    Steven H. Ferris
    Richard Mohs
    Ronald G. Thomas
    Kimberly Schafer
    Karen Campbell
    Ann Marie Hake
    Barbara Schoos
    Leon J. Thal
    Journal of Molecular Neuroscience, 2002, 18 : 283 - 293
  • [29] A phase I study of AIT-082 in healthy elderly volunteers
    Grundman, M
    Farlow, M
    Peavy, G
    Kim, HT
    Capparelli, E
    Schultz, AN
    Salmon, DP
    Ferris, SH
    Mohs, R
    Thomas, RG
    Schafer, K
    Campbell, K
    Hake, AM
    Schoos, B
    Thal, LJ
    JOURNAL OF MOLECULAR NEUROSCIENCE, 2002, 18 (03) : 283 - 293
  • [30] AUTOLOGOUS CELL TREATMENT FOR SKIN: A PHASE I TRIAL WITH HEALTHY VOLUNTEERS
    Nakamura, H.
    Panich, D.
    Marksteiner, R.
    Magnus, B.
    Hoffmann, R.
    McElwee, K.
    Hall, D.
    Buckler, L.
    CYTOTHERAPY, 2016, 18 (06) : S44 - S44